AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05843318 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water Intake and weight control in older adults - hypocaloric diet alone
Description: Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive instructions in the hypocaloric diet, without specific fluid intake recommendations.
Study NCT05085275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Citrate 1 GM Oral Tablet [AURYXIA]
Description: All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
Study NCT05085275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
Study NCT05278078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: psychological support
Description: psychological support will be given to the patients in the experimental group.
Study NCT05278078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nutritional education
Description: nutritional education will be given to the patients in the experimental group.
Study NCT05278078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: psychological support and nutritional education
Description: psychological support and nutritional education will be given to the patients in the experimental group.
Study NCT05278078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intervation
Description: No intervention will be applied to the control group
Study NCT06110429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactate, Sodium
Description: Isovolemic and osmotic infusion Comparison of osmotic agent
Study NCT06110429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: Isovolemic and osmotic infusion Comparison of osmotic agent
Study NCT05612633 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: zelavespib
Description: Oral zelavespib 100 mg will be administered once daily
Study NCT05920408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXS21546
Description: EXS21546 Granule in Capsule
Study NCT05693454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infiltration with NaCl
Description: Local wound infiltration at the end of spine surgery with NaCl
Study NCT05693454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration with Ropivacain
Description: Local wound infiltration at the end of spine surgery with Ropivacain
Study NCT05693454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration with a combination of Levobupivacaine and Tramadol
Description: Local wound infiltration at the end of spine surgery with a combination of Levobupivacaine and Tramadol
Study NCT05269030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Topical
Description: Ivermectin 1% in a dose of two drops per nostril twice daily.
Study NCT05269030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide Nasal
Description: 64 µg per puff in a dose of 1 puff for each nostril twice daily.
Study NCT06172400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine, Combinations
Description: Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.
Study NCT06172400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine, Combinations
Description: Using local anesthesia with adrenaline for intraoperative vasoconstriction instead of a tourniquet.
Study NCT04867265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mout-to-mouth ventilation
Description: we will record the visibility of chest rising
Study NCT04867265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mout-to-mouth ventilation with quantitative analysis
Description: we will record the visibility of chest rising, review the ventilation metrics and evaluate each rescue breath in QCPR Skill Reporter
Study NCT05397665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT-007
Description: AT-007, aldose reductase inhibitor
Study NCT05397665 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Liquid oral suspension
Study NCT05792306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The novel electrolyzed water spray
Description: The researcher use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
Study NCT05792306 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The saline spray
Description: The researcher use saline to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
Study NCT05517798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation
Description: Alveolar ridge preservation is a method of decreasing bone resorption following tooth extraction and facilitating prosthetically-driven implant placement
Study NCT05640609 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Capeox regimen combined with Sintilimab and Bevacizumab
Description: Stage Ib：Oxaliplatin +Capecitabine Tablets +Sintilimab +Bevacizumab Stage II：Bevacizumab (the dose determined in phase Ib clinical study)，the dosage of other drugs was the same as before
Study NCT04683458 — intervention group
Intervention type: DEVICE
Intervention: Drug-coated device
Description: The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
Study NCT06179316 — intervention group
Intervention type: PROCEDURE
Intervention: Robot Assisted Radical Prostatectomy
Description: Performing radical prostatectomy operation using robotic equipment while preserving bilateral nerve bundles
Study NCT05567770 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Cohort 1 patients with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
Study NCT04279158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: experience 1 The negative priming task
Description: The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.
Study NCT04279158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience 1 The negative priming task
Description: The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.
Study NCT04279158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: experience 2 Stop signal task
Description: The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target
Study NCT05567770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen Deprivation Therapy
Description: Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
Study NCT04279158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience 2 Stop signal task
Description: The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target
Study NCT06552182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344
Description: per oral
Study NCT06552182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344-R1, HUC2-344-R2
Description: per oral
Study NCT05163353 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment with diluted Radiesse
Description: Injection of Décolleté Wrinkles with diluted Radiesse
Study NCT05163353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with diluted Radiesse
Description: Injection of Décolleté Wrinkles with diluted Radiesse
Study NCT06292429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex Training
Description: Week 1-4: Foundation Phase Lower Body Resistance Training Squats (Back Squats or Goblet Squats) Deadlifts Lunges~Paired with:~Box Jumps Depth Jumps~Upper Body Resistance Training Bench Press Overhead Press~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw Rows (Barbell or Dumbbell)~Week 5-8: Strength and Power Phase Lower Body Resistance Training Power Cleans Front Squats Romanian Deadlifts~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Push Press Pull-Ups or Lat Pulldowns Bent Over Rows~Paired with:~Plyometric Push-Ups Medicine Ball Slam~Week 9-12: Power and Speed Phase Lower Body Resistance Training Snatch Split Squats Jumping Lunges~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Speed Bench Press Face Pulls Plyometric Pull-Ups~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw
Study NCT06292429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Week 0-4 Session 1 Rotator cuff wall compression Forearm flexor compression Alpha ball tricep scrape Band assisted pushups Session 2 Soft ball thoracic breathing Neck ball arm rotations ITb compressions Middle quard compressions~Week 4-8 Session 1 Kneeling pall of band hold Kneeling pall of partner proturbations Leg lower with mediball neutral Half lying arm speed and swing drill Session 2 Single leg band hold Trunk activated psoas lowers Split clam Bulgarian split iso hold~Week 8-12 Session 1 Point kneel thoracic rotations Side lying single arm thoracic abduction Banded side lying clams Side lying abduction from glute Session 2 Low back mobility Kneeling pall off band hold Clean and jerks power drill movements Weighted bench press Session 3 Standing band rotations thoracic only Band pull aparts Tennis ball in trap arm flexion ext thumb to floor Bulgarian weighted
Study NCT06292429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: No intervention given
Study NCT06286735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cinnamomum
Description: 60 capsules of 500 mg of powdered cinnamomum bark (Cinnamomum verum; 40% polyphenols). Participants in this group will be instructed to consume two capsules per day, one after lunch and one after dinner for 3 months.
Study NCT06286735 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 capsules with 500 mg of corn starch per month, until the end of the three months of intervention. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
Study NCT05241756 — intervention group
Intervention type: DEVICE
Intervention: FLACS using FEMTO LDV-Z8
Description: Performance of femtosecond laser-assisted capsulotomy in the anterior capsule.
Study NCT06092411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Depression
Description: Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
Study NCT06092411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy for Depression
Description: Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
Study NCT06092411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).
Study NCT04279158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: experience 3 Anti-saccades
Description: The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target
Study NCT04279158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience 3 Anti-saccades
Description: The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target
Study NCT06087978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C RPT193
Description: Radiolabelled RPT193
Study NCT04519060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phototherapy eye shield
Description: Phototherapy eye shields will be applied to the eyes of infants dilated for scheduled eye exam. They will be worn until four (4) hours after the last dose of dilating eye drops.
Study NCT04315636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactant nebulisation
Description: 200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).
Study NCT05943197 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dental prosthetics, biofilm response and oral microbiota
Description: microbiota, biofilm, oral mucosa
Study NCT05105815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPM001
Description: IPM001 will be used against tumor cells
Study NCT01970124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, High dose
Study NCT01970124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, Low dose
Study NCT06214039 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety
Description: A 3-hour one session exposure therapy for public speaking anxiety
Study NCT06214039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety
Description: A 3-hour one session exposure therapy for public speaking anxiety
Study NCT04806334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI imaging of the pelvis/bladder
Description: The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI).
Study NCT04806334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: genomic analysis of tumor
Description: Single cell RNA sequencing of transurethral resection of bladder tumor (TURBT)
Study NCT05994664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heartmath Intervention
Description: The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. During the initial visit for the intervention group the same assessment will be included, however, they will also receive 10-15 of instruction on a basic Heartmath technique. Group participants will be asked to complete 5-10 minutes of HeartMath techniques 2x daily. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. However, each week the intervention group will receive an addition 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.
Study NCT05994664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. The initial visit will include an HRV assessment using the HeartMath sensor via the 3-step Protocol developed by the HeartMath Institute. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.
Study NCT04844086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPM CD19-mbIL15-CAR-T cells
Description: Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard 3+3 design will be applied.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion
Study NCT04631536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol
Description: active Comparator: Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc). Treatment to be continued until 14 days or discharge/death whichever occurs first. It includes: Nebivolol 5 mg PO daily, Sigmart 10 mg PO twice daily, Atorvastatin 40 mg PO daily, Folic Acid 5 mg PO daily, L-arginine 1000 mg PO 3 times daily.
Study NCT04631536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
Study NCT01970137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, High dose
Study NCT01970137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, Low dose
Study NCT05022303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larazotide Acetate
Description: AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
Study NCT05022303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
Study NCT06329921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PTT protocol
Description: Patients will be monitored using the nurse-managed PTT protocol.
Study NCT06329921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anti-Xa protocol
Description: Patients will be monitored using the pharmacy-managed anti-Xa protocol.
Study NCT04944186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Pressure Injury Patient Education (mySPIPE)
Description: It consists of PI education topics which include four main topics; 1) Pressure Injury: Why Me, which will be covering the basic information that patient need to know about PI; 2) Look After Your Skin, in this topics, patient will be thought about how skin checking was done and why it need to be done; 3) Preventing pressure injury, in this topic, patient will be emphasized on the suitable repositioning for them and the benefit of support surfaces and preventive wound dressing; 4) Help your PI heal, in this topic patient will be guided on what are condition that help PI healing and dietary needs to support wound healing
Study NCT04944186 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Patient Education
Description: No fixed content/ duration of patient education. Basically, patient repositioning emphasized verbally after wound dressing completed.
Study NCT06172205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous FOLFOX7 plus Camrelizumab and apatinib
Description: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days
Study NCT06172205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAIC-FOLFOX plus Camrelizumab and apatinib
Description: 2-h infusion of oxaliplatin at 85 mg/m2 ,a 2-3-h administration of leucovorin at 400 mg/m2 , and a 46-h delivery of fluorouracil at 2500 mg/m2.~camrelizumab (200 mg intravenously, commencing in 7 days after the first HAIC cycle and repeated every 21 days) and apatinib (250 mg daily, taken orally, beginning in 7 days after the initial HAIC cycle) Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days
Study NCT05006508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle tool
Description: Regular use of the digital Lifestyle tool